Dexcom stock heads into the open after a 0.8% Nasdaq pullback

Dexcom stock closed at USD 84.51 on the Nasdaq on September 10, 2026, gaining about 2.1% from the prior session in a weak broader market. The move came as the Nasdaq Composite fell roughly 0.7% the same day, leaving Dexcom comparatively resilient against the tech-heavy index.

September 10, 2026 in numbers

Dexcom Inc. (ISIN US2521311074, Nasdaq: DXCM) ended the September 10, 2026 session at USD 84.51, up about 2.1% from a previous close near USD 82.74 according to Nasdaq data from MarketWatch and Business Insider. Per Nasdaq figures, the share’s intraday range stayed consistent with this close, and trading volume on the day remained within its recent average, while the Nasdaq Composite slipped about 0.7% on September 10, 2026 per a wrap from Zacks and a major-index summary at Las Vegas Sun.

As StockTitan reported in a September 10, 2026 filing summary, Dexcom expanded its board of directors to thirteen members and appointed Glenn S. Boehnlein as an independent director effective that date, an update that added a governance angle to the stock’s session profile. In parallel, TipRanks highlighted the appointment and cited the stock’s recent analyst stance as a buy, underscoring continued positive coverage despite sector volatility.

Events and signals today

As of today, September 11, 2026, no new earnings release or annual meeting is scheduled for Dexcom within the next few trading days in major earnings calendars, so investor attention remains on how the market digests the fresh board appointment and prior quarter fundamentals already reported earlier this week. According to MarketBeat, Dexcom most recently posted quarterly earnings per share of USD 0.70 on revenue of USD 1.31 billion, both ahead of consensus, which continues to frame expectations around the stock into today’s session even as broader Nasdaq volatility and health-care sentiment may influence short-term moves.